WO2004013629A3 - Composes organiques - Google Patents

Composes organiques Download PDF

Info

Publication number
WO2004013629A3
WO2004013629A3 PCT/EP2003/008313 EP0308313W WO2004013629A3 WO 2004013629 A3 WO2004013629 A3 WO 2004013629A3 EP 0308313 W EP0308313 W EP 0308313W WO 2004013629 A3 WO2004013629 A3 WO 2004013629A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
screening
treatment
agents suitable
associated inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/008313
Other languages
English (en)
Other versions
WO2004013629A2 (fr
Inventor
Sau Wei Li
Christopher Terence Poll
John Westwick
Martin Gosling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0217503.2A external-priority patent/GB0217503D0/en
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Priority to AU2003251650A priority Critical patent/AU2003251650A1/en
Priority to JP2004525342A priority patent/JP2005534311A/ja
Priority to EP03766324A priority patent/EP1527343A2/fr
Publication of WO2004013629A2 publication Critical patent/WO2004013629A2/fr
Publication of WO2004013629A3 publication Critical patent/WO2004013629A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une analyse de substances qui modulent l'activité d'un polypeptide codé par un gène 6 potentiel récepteur transitoire humain (TRPC6). L'analyse consiste à combiner une substance candidate avec le polypeptide et à mesurer l'effet de ladite substance sur l'activité dudit polypeptide. De telles substances peuvent servir dans la préparation de produits pharmaceutiques destinés à traiter des maladies inflammatoires, en particulier celles associées aux leucocytes.
PCT/EP2003/008313 2002-07-29 2003-07-28 Composes organiques Ceased WO2004013629A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003251650A AU2003251650A1 (en) 2002-07-29 2003-07-28 Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
JP2004525342A JP2005534311A (ja) 2002-07-29 2003-07-28 白血球関連炎症性疾患の処置に適する作用因子のスクリーニング
EP03766324A EP1527343A2 (fr) 2002-07-29 2003-07-28 Composes organiques

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0217503.2 2002-07-29
GBGB0217503.2A GB0217503D0 (en) 2002-07-29 2002-07-29 Organic compounds
US41512402P 2002-09-30 2002-09-30
US60/415,124 2002-09-30

Publications (2)

Publication Number Publication Date
WO2004013629A2 WO2004013629A2 (fr) 2004-02-12
WO2004013629A3 true WO2004013629A3 (fr) 2004-05-06

Family

ID=31497250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008313 Ceased WO2004013629A2 (fr) 2002-07-29 2003-07-28 Composes organiques

Country Status (4)

Country Link
EP (1) EP1527343A2 (fr)
JP (1) JP2005534311A (fr)
AU (1) AU2003251650A1 (fr)
WO (1) WO2004013629A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098709B (zh) * 2005-01-12 2012-06-20 塞诺菲-安万特股份有限公司 Trpc通道治疗心血管疾病的用途
EP2052724A1 (fr) * 2007-10-26 2009-04-29 sanofi-aventis Utilisation de norgestimate en tant qu'inhibiteur sélectif de canal d'ion TRPC3, TRPC6 et TRPC6 et TRPC7
KR100953821B1 (ko) * 2007-12-03 2010-04-21 순천향대학교 산학협력단 비타민 ｄ 결합 단백질을 이용한 천식 진단 마커 및 천식치료제
EP2368876A1 (fr) * 2010-03-01 2011-09-28 Sanofi Dérivés d'aminoindanes, leur préparation et leur application en thérapeutique
US9790551B2 (en) 2013-02-04 2017-10-17 Aging Wise Biotechnology, Inc. Use of TRPC6 mRNA levels in peripheral blood cells for early detection/diagnosis of senile dementia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025063A1 (fr) * 1996-01-11 1997-07-17 The Wellesley Hospital Foundation Compositions contenant des antagonistes calciques pour inhiber la croissance cellulaire
WO2000004929A1 (fr) * 1998-07-24 2000-02-03 South Alabama Medical Science Foundation Utilisation de niveaux reduits d'un produit genique fonctionnel a potentiel de recepteur transitoire
WO2002048342A2 (fr) * 2000-12-11 2002-06-20 Deltagen, Inc. Souris transgeniques presentant des interruptions du gene trp6 au niveau du canal ion calcium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025063A1 (fr) * 1996-01-11 1997-07-17 The Wellesley Hospital Foundation Compositions contenant des antagonistes calciques pour inhiber la croissance cellulaire
WO2000004929A1 (fr) * 1998-07-24 2000-02-03 South Alabama Medical Science Foundation Utilisation de niveaux reduits d'un produit genique fonctionnel a potentiel de recepteur transitoire
WO2002048342A2 (fr) * 2000-12-11 2002-06-20 Deltagen, Inc. Souris transgeniques presentant des interruptions du gene trp6 au niveau du canal ion calcium

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAERSCH, G. ET AL: "Differential effects of two calcium channel blockers on bronchial smooth muscle", ARZNEIMITTEL-FORSCHUNG, vol. 45, no. 12, 1995, pages 1294 - 1297, XP008027738 *
CHUNG, S. ET AL: "Inhibition by SK&F 96365 of Ca2+ current, IL-2 production and activation in T lymphocytes", BRITISH JOURNAL OF PHARMACOLOGY, vol. 113, no. 3, 1994, pages 861 - 868, XP008027740 *
INOUE R. ET AL: "The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel", CIRCULATION RESEARCH, vol. 88, no. 3, 2001, pages 325 - 332, XP002220260, ISSN: 0009-7330 *
TIRUPPATHI C ET AL: "IMPAIRMENT OF STORE-OPERATED CA2+ ENTRY IN TRPC4-/- MICE INTERFERES WITH INCREASE IN LUNG MICROVASCULAR PERMEABILITY", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 91, no. 1, July 2002 (2002-07-01), pages 70 - 76, XP008010300, ISSN: 0009-7330 *

Also Published As

Publication number Publication date
AU2003251650A8 (en) 2004-02-23
WO2004013629A2 (fr) 2004-02-12
JP2005534311A (ja) 2005-11-17
AU2003251650A1 (en) 2004-02-23
EP1527343A2 (fr) 2005-05-04

Similar Documents

Publication Publication Date Title
Longley et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
AU2003212729A1 (en) Vitamin d upregulated protein 1 (vdup-1) methods and uses thereof
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
EP1140840A4 (fr) Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
WO2003000853A3 (fr) Essais pour agregation de proteines, et utilisations
WO2005059106A3 (fr) Anticorps contre l'interferon alpha et leur utilisations
WO2004044168A3 (fr) Rapporteurs fluorescents codes genetiquement presentant des activites de kinase, de methyltransferase et d'acetyltransferase
WO2004074486A3 (fr) Proteines de fusion de muteines d'interferon-alpha aux proprietes ameliorees
EP2402372A3 (fr) Agent thérapeutique
WO2004005481A3 (fr) Procedes d'identification de modulateurs de l'apoptose a mediation assuree par mda-7
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT820303E (pt) Analogos do peptido p277 e composicoes farmaceuticas que os compreendem, para tratamento ou diagnostico de diabetes
NZ334518A (en) Homocysteine desulphurase from the protozoan trichomonas vaginalis
WO2000012703A3 (fr) Molecules associees au transport de proteines
WO2004013629A3 (fr) Composes organiques
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DK0983361T3 (da) Bakterielle pheromoner og anvendelser deraf
WO2004048550A3 (fr) Proteines associees a une reponse immune
WO2004005540A3 (fr) Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses
WO2003072606A3 (fr) Agents de liaison de glycoproteines cd44 et methodes d'utilisation associees
WO2006063009A3 (fr) Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ceux-ci sur la base de proteines exprimees differemment dans le serum
EP1199372A3 (fr) Polymorphismes du gène humain P2X7
WO2005058358A3 (fr) Utilisation d'agents derives de ceacam1 pour le traitement de maladies inflammatoires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SY TJ TM TN TR TT UA US UZ VC VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003766324

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004525342

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003766324

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003766324

Country of ref document: EP